Advertisement

Pharmacy World & Science

, Volume 29, Issue 1, pp 12–18 | Cite as

The effects of introducing a clinical pharmacist on orthopaedic wards in Denmark

  • Thomas Croft BuckEmail author
  • Lene Brandstrup
  • Ivan Brandslund
  • Jens Peter Kampmann
Article

Abstract

Objective

To assess the effects and cost effects of introducing clinical pharmacists on hospital wards.

Methods

Comparative prospective study on four orthopaedic surgical wards in two hospitals. The primary effect variables were 10 target areas widely considered to be indicators of good prescription practice. Prescriptions not following good practice in these intervention areas were defined as “sub-optimal prescriptions,” and then discussed between a physician and a clinical pharmacist. The primary parameter was the difference in the number of days with a sub-optimal prescription (Mann–Whitney test).

Results

On an average 20% of all the patients had a sub-optimal prescription. Of these, 70% were changed by the physician after intervention by the clinical pharmacist. There was a statistically significant difference in the duration of days in treatment with a sub-optimal prescription. Where sub-optimal prescriptions were changed, 43% resulted in cost reductions. The reductions achieved could cover 47% of the costs of clinical pharmacy service.

Conclusions

Clinical pharmacy services offered to four orthopaedic surgical wards resulted in reduction of sub-optimal prescriptions. Every time the pharmacist screened seven patients one sub-optimal prescription was found and adjusted. The reduction in medicine costs due to adjusted sub-optimal prescriptions could not cover the whole cost of clinical pharmacy service.

Keywords

Clinical pharmacy Clinical pharmacy service Clinical pharmacist Medical prescription Quality assessment  

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
  2. 2.
    Phillips D, Christenfeld N and Glynn L (1998). Increase in US medication-error deaths between 1983 and 1993. Lancet 351: 643–644CrossRefPubMedGoogle Scholar
  3. 3.
    Nelson KM and Talbert RI (1996). Drug-related hospital admissions. Pharmacotherapy 16: 701–707PubMedGoogle Scholar
  4. 4.
    Hallas J (1996). Drug related hospital admissions in subspecialities of internal medicine. Dan Med Bull 43: 6–8Google Scholar
  5. 5.
    Wiffen P, Gill M, Edwards J, Moore A. Adverse drug reactions in hospital patients. http://www.jr2.ox.ac.uk/bandolier/extraforbando/adrom.pdf.
  6. 6.
    Schumock GT, Butler MG, Meek PD and Vermeulen LC (2003). Evidence of the economic benefit of clinical pharmacy services 1996–2000. Pharmacotherapy 23: 113–132CrossRefPubMedGoogle Scholar
  7. 7.
    Cotter SM, Barber ND and McKee M (1994). Survey of clinical pharmacy services in United Kingdom National Health Service Hospitals. Am J Hosp Pharm 51: 397–405Google Scholar
  8. 8.
    Morrison A and Wertheimer AI (2001). Evaluation of studies investigating the effectiveness of pharmacists clinical services. Am J Health Syst Pharm 58: 569–577PubMedGoogle Scholar
  9. 9.
    Navrbjerg PK and Zederkof S (1998). Rationel farmkoterapi på plejehjem. Månedsskr prakt lægegern 76: 563–569Google Scholar
  10. 10.
    Child D, Cantrill J and Cooke J (2004). Effectiveness of hospital pharmacy in the UK: methodology for finding the evidence. Pharm World Sci 26: 44–51CrossRefPubMedGoogle Scholar
  11. 11.
    Hatoum HT and Akhras K (1993). 32-year literature review on the value and acceptance of ambulatory care provided by pharmacists. Bioliography Ann Pharmacother 27: 1106–1119Google Scholar
  12. 12.
    Lægemiddelkataloget (The Danish National Formulary) (2001) ISBN: 0105-287XGoogle Scholar
  13. 13.
    Weil J, Colin-Jones D and Wainwright P (1995). Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 310: 827–830PubMedGoogle Scholar
  14. 14.
    Dutch TIA Trial Study Group. (1991). Comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 325(18): 1261–1266CrossRefGoogle Scholar
  15. 15.
    Silverstein FE, Faich G and Geis GS (2000). Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib long-term arthritis safety study. JAMA 284: 1247–1255CrossRefPubMedGoogle Scholar
  16. 16.
    Institute for Rational Pharmacotherapy. http://www.irf.dk/dk/publikationer/maanedsblad/nasid_-_oemme_punkter.htm.. (10 Aug. 2002)
  17. 17.
    Institute for Rational Pharmacotherapy. http://www.irf.dk/dk/praeparatnyt/arkiv/celecoxib_celebra_02.htm.. (10 Aug. 2002)
  18. 18.
    Greer IA, Gibson JL and Young A (1999). Effect of ketorolac and low-molecular-weight heparin individually and in combination on haemostasis. Blood Coagul Fibrin 10: 367–373CrossRefGoogle Scholar
  19. 19.
    O’Neil-Cutting MA and Crosby WH (1986). The effect of antacids on the absorption of simultaneously ingested iron. JAMA 255: 1468–1470CrossRefPubMedGoogle Scholar
  20. 20.
    Eriksen J, Sjøgren P, Jensen NH (2000) Praktisk klinisk smertebehandling, pp. 56–139. ISBN 87-16-12296-8Google Scholar
  21. 21.
    Jorgensen AW and Sorensen OH (1970). Digitalis intoxication. A comparative study on the incidence of digitalis intoxication during the periods 1950-1952 and 1964–1966. Acta Med Scand 188(3): 179–183PubMedGoogle Scholar
  22. 22.
    Michalko KJ and Blain L (1987). An evaluation of a clinical pharmacokinetic service for serum digoxin levels. Drug Monit 9: 311–319CrossRefGoogle Scholar
  23. 23.
    McMullin ST, Hennenfelt JA and Bailey TC (1999). A prospective, randomized trial to assess the cost of pharmacist-initiated intervention. Arch Intern Med 159: 2306–2309CrossRefPubMedGoogle Scholar
  24. 24.
    Cowper A, Weinberger M and Feussner JR (1998). The Cost-effectiveness of clinical pharmacist intervention among outpatients. Pharmacotherapy 18(2): 327–332PubMedGoogle Scholar
  25. 25.
    Weinberger M, Murray MD and Marrero DG (2002). Effectiveness of pharmacist care for patients with reactive airways disease: a randomized controlled trial. JAMA 288(13): 1594–1602CrossRefPubMedGoogle Scholar
  26. 26.
    Malone DC, Carter BL and Billups SJ (2001). Can clinical pharmacists affect SF-36 scores in veterans at high risk for medication-related problems?. Med Care 39(2): 113–122CrossRefPubMedGoogle Scholar
  27. 27.
    Vivian EM (2002). Improving blood pressure control in a pharmacist-managed hypertension clinic. Pharmacotherapy 22(12): 1533–1540CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2007

Authors and Affiliations

  • Thomas Croft Buck
    • 1
    Email author
  • Lene Brandstrup
    • 2
  • Ivan Brandslund
    • 3
  • Jens Peter Kampmann
    • 4
  1. 1.Health DepartmentVejle CountyVejleDenmark
  2. 2.Pharmacy DepartmentHospital of VejleVejleDenmark
  3. 3.Department of Clinical BiochemistryHospital of VejleVejleDenmark
  4. 4.Institute for Rational PharmacotherapyDanish Medicines AgencyCopenhagenDenmark

Personalised recommendations